SAGA presenting at the EACR-OECI virtual conference: Molecular Pathology Approach to Cancer on March 23-24

Molecular pathology is revolutionizing clinical practice in oncology and pathology paving the way for precision medicine, and has evolved into a growing research field.  


SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, is proud to participate at the EACR-OECI joint virtual conference on “Molecular Pathology Approach to Cancer” on March 23rd & 24th, 2021.


Visit the conference website at


This meeting will provide participants with a broad view of the scope, methodologies, future directions, and challenges for molecular pathology in research and in clinical settings, as well as provide insights to practical approaches.


At the on-demand satellite symposia, Dr. Lao Saal, CEO of SAGA Diagnostics and Berta Kamprad Associate Professor at the Division of Oncology, Lund University, will give an oral presentation of the SAGA technologies SAGAsafe®, SAGAsign®, and SAGAseq® for ultrasensitive cancer diagnostics and circulating tumor DNA (ctDNA) monitoring.  The presentation video will also be made available following the conference.


SAGA technologies address the needs of biopharma, investigators, and hospital systems to identify actionable variants at an earlier stage, measure residual disease and treatment response, and empower better therapeutic decisions.  In such a way, SAGA enables molecular translational research, high-yield clinical trials, and ultimately can lead to improved quality of life for cancer patients and better outcomes.


In addition, please find us live at our virtual booth, where you can download additional product resources and have the opportunity for a chat with one of our representatives. SAGA is looking forward to speaking with you at the conference.




Director of Market Access Annina Hube, PhD MBA  [email protected]  Phone: +46 (0) 733 01 7242


About SAGA Diagnostics AB
SAGA Diagnostics is a personalized cancer genomics and disease monitoring company that offers molecular genetic testing of tissue biopsies and non-invasive “liquid biopsies” such as blood samples. SAGA helps pharmaceutical companies, scientists, and healthcare providers to detect actionable mutations, stratify patient groups, and monitor treatment response more accurately and to an industry-leading lower limit of detection of 0.001%. Analysis of circulating tumor DNA using its proprietary technologies gives SAGA unique ultrasensitivity, and provides the basis for optimal decision-making.

Follow SAGA on Twitter @SAGAdiagnostics and LinkedIn.